Scope: ADME testing, metabolite profiling, transporter studies, pharmacogenomics, clinical specimen bioanalysis
Differentiators: GCLP-certified, >95% regulatory coverage, seamless non-clinical to clinical support
Target Compounds: Small molecules, peptides, ADCs, nanomedicines, biologics
Specimens: Animal/human blood, urine, tissues from non-clinical or clinical samples
Study Design: IND/NDA-ready, IVIVE and PBPK modeling consultation

* Main ADME service items

• Absorption: Caco-2, PAMPA (intestine, BBB, skin)

• Distribution: Plasma/microsomal protein binding (RED, ultrafiltration), blood-brain membrane penetration

• Metabolism: Hepatic endoplasmic reticulum, S9, hepatocyte and enterocyte-based metabolic stability, metabolite identification and inhibition (IC₅₀, Kᵢ, kₐₙₐc/Kᵢ), enzyme expression induction (PXR, etc.)

• Transporters: ABC/SLC-based substrate and inhibition tests, induction tests (OAT, OATP, MATE, NTCP, etc.)

• Pharmacogenomics (PGx): Enzyme phenotyping based on wild-type and mutant metabolic enzymes

* Physiological and biochemical analysis

• Evaluation of physicochemical properties: Solubility (thermodynamic, turbidimetric), stability (FaSSIF, FeSSIF, SGF, SIF)

• BCS-based Biowaiver: Solubility, permeability, analysis for MFDS report

• Biochemical analysis: LC-MS/MS, PK analysis, immunoassay-based

* Linkage to clinical trials Services

• Blood/urine sample-based human metabolome analysis, pharmacogenetic testing, microdosing (including AMS)

• IVIVE and PBPK modeling-based data consulting and application